Creating a prediction score for lung transplant or death in Alpha-1 Antitrypsin Deficiency
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study is creating a simple scoring system to predict who with Alpha-1 Antitrypsin Deficiency-related emphysema might need a lung transplant or die from the disease. Your medical records from 2010–2025 will help build this tool, with no extra tests or visits required.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with emphysema or COPD caused by a specific genetic condition (Alpha-1 Antitrypsin Deficiency) between 2010 and 2025.
- You have one of the severe genetic types (like PiZZ or other rare mutations).
- A CT scan of your chest confirmed emphysema within a year of your diagnosis.
- You are at least 18 years old.
- You have not objected to your medical data being used for research, and you are covered by a social security plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at people with a specific mild form of alpha-1 antitrypsin deficiency (PiMZ) to understand how their lung disease progresses over time. It involves lung function tests and CT scans, and may help researchers learn more about the condition.
This trial tests a gene therapy to fix the genetic cause of alpha-1 antitrypsin deficiency, aiming to stop or slow emphysema. It is for people with the most common harmful gene variants who have mild to moderate lung damage and are otherwise healthy enough to take steroids safely.
This study uses artificial intelligence to analyze CT scans and other health data to better identify people at risk for smoking-related diseases like lung cancer. Researchers hope to improve early detection and prevention.
This trial tests a new treatment called BEAM-302, which aims to correct the genetic defect that causes alpha-1 antitrypsin deficiency. It may help prevent further lung and liver damage in people with the PiZZ mutation.
This study looks at how lung disease changes a type of blood cell called white blood cells. It may help researchers understand what’s happening in the lungs and how to better monitor or treat lung problems.
This study uses advanced blood and tissue testing to predict how well a new lung will work after transplant. If you've had a lung transplant and are stable, you may help researchers improve care for future patients.
Hear when a new Alpha 1-Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.